Powershares Dynamic Pharmaceuticals Etf ETF News

Citadel Advisors LLC acquired a new stake in shares of Invesco Dynamic Pharmaceuticals ETF (NYSEARCA:PJP) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 12,660 shares of the companys stock, valued at approximately $1,019,000. Citadel Advisors LLC owned about 0.23% of Invesco Dynamic Pharmaceuticals []

Morgan Stanley decreased its holdings in shares of Invesco Dynamic Pharmaceuticals ETF (NYSEARCA:PJP) by 6.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 38,415 shares of the companys stock after selling 2,532 shares during the period. Morgan Stanley owned approximately 0.70% of Invesco Dynamic Pharmaceuticals ETF worth [] The post Morgan Stanley Sells 2,532 Shares of Invesco Dynamic Pharmaceuticals ETF (NYSEARCA:PJP) appeared first on ETF Daily News .

Smart Beta ETF report for PJP

The S&P 500 Health Care Index is up 18% year-to-date, an admiral though not spectacular performance. While coronavirus vaccines remain a point of much discussion, pharmaceuticals stocks also fit the bill as solid though not spectacular. However, there are still reasons to consider exchange traded funds like the Invesco Dynamic Pharmaceuticals ETF (NYSEArca: PJP). PJP [] The post Economics, Patents Critical for Pharmaceuticals Innovation, Equity Prices appeared first on ETF Trends .

The S&P 500 Health Care Index is up 18% year-to-date, an admiral though not spectacular performance. While coronavirus vaccines remain a point of much discussion, pharmaceuticals stocks also fit the b

The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.

Sector ETF report for PJP

The healthcare sector is getting its groove back, as a variety of exchange traded funds dedicated to the group are printing or residing near new highs. The Invesco Dynamic Pharmaceuticals ETF (NYSEArc

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

The slew of Q1 results have led to mixed trading in pharma ETFs over the past month.

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,

The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.